Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs TransMedics Group Inc — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.85 (market cap $1.45B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days and TransMedics Group Inc for 24 Days on average.
| QQQE | TMDX | |
|---|---|---|
Market Cap | $1.45B | $2.74B |
Volume | 323,568 | 949,331 |
Sector | Broad Market / Factor | Health |
52-Week High | $124.69 | $150.42 |
52-Week Low | $96.06 | $61.99 |
Typical Hold Time | 48 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE, the Direxion NASDAQ-100 Equal Weighted Index ETF, trades at $121.68, down 0.17% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators are neutral. The equal-weight strategy reduces technology concentration compared to the standard NASDAQ-100 ETF, offering diversified exposure to large-cap growth stocks. Recent news highlights tactical preference for QQQE over QQQ due to its fundamental and technical positioning.
The outlook for QQQE is positive, driven by its equal-weight approach mitigating single-stock risk and capturing broad Nasdaq growth. Key risks include market volatility and sector concentration shifts. Investment appeal lies in its structural diversification, though reliance on tech sector performance remains a factor for investors to weigh.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
